Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Designing clinical protocols for optimal use: measuring attributes of treatment and cancer control trials.

Literature DB >> 1812186

Designing clinical protocols for optimal use: measuring attributes of treatment and cancer control trials.

J E Veney¹, W P Kory, J M Barnsley, A D Kaluzny.

Abstract

The design of clinical protocols is an important factor in assuring patient accrual and compliance. This paper describes the methods used to assess the attributes of treatment and cancer control research protocols. Measures are presented for assessing three attributes considered important: relative advantage, complexity, and compatibility.

Entities: Disease Species

Mesh：

Year: 1991 PMID： 1812186 DOI： 10.1007/BF00995972

Source DB: PubMed Journal: J Med Syst ISSN： 0148-5598 Impact factor: 4.460

Keyword Cloud
References

22 in total

1. Randomized clinical trials. Perspectives on some recent ideas.

Authors: D P Byar; R M Simon; W T Friedewald; J J Schlesselman; D L DeMets; J H Ellenberg; M H Gail; J H Ware
Journal: N Engl J Med Date: 1976-07-08 Impact factor: 91.245

2. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials.

Authors: J A Freiman; T C Chalmers; H Smith; R R Kuebler
Journal: N Engl J Med Date: 1978-09-28 Impact factor: 91.245

Designing clinical protocols for optimal use: measuring attributes of treatment and cancer control trials.

1. Randomized clinical trials. Perspectives on some recent ideas.

2. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials.

3. Can a clinical trial be the treatment of choice for patients with cancer?

4. Barriers and incentives for primary care physicians in cancer prevention and detection.

Review 5. Physician utilization. The state of research about physicians' practice patterns.

6. The crisis in clinical cancer research. Third-party insurance and investigational therapy.

7. Why doctors don't disclose uncertainty.

8. The Lugano statements on controlled clinical trials.

9. Impediments to recruitment in the Canadian National Breast Screening Study: response and resolution.

10. Evaluating organizational design to assure technology transfer: the case of the Community Clinical Oncology Program.